Novartis AG (NOVN) Stock Forecast & Price Target

Compare

35 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOVN Analyst Ratings

Moderate Buy

7 Buy

3 Hold

2 Sell

Based on 12 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOVN Stock 12 Month Forecast

Average Price Target

CHF107.18

▲(1.67% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is CHF107.18 with a high forecast of CHF125.00 and a low forecast of CHF90.00. The average price target represents a 1.67% change from the last price of CHF105.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","105":"CHF105","126":"CHF126","94.5":"CHF94.5","115.5":"CHF115.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF107.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,94.5,105,115.5,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.26,105.85538461538462,107.45076923076924,109.04615384615386,110.64153846153846,112.23692307692308,113.8323076923077,115.42769230769231,117.02307692307693,118.61846153846155,120.21384615384616,121.80923076923077,123.40461538461538,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.26,104.4846153846154,104.70923076923077,104.93384615384616,105.15846153846154,105.38307692307693,105.60769230769232,105.8323076923077,106.05692307692308,106.28153846153847,106.50615384615385,106.73076923076924,106.95538461538462,{"y":107.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.26,103.16307692307693,102.06615384615385,100.96923076923078,99.8723076923077,98.77538461538462,97.67846153846153,96.58153846153846,95.48461538461538,94.3876923076923,93.29076923076923,92.19384615384615,91.09692307692308,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF125.00

Average Price TargetCHF107.18

Lowest Price TargetCHF90.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Vosser

J.P. Morgan

CHF95→CHF125

Buy

18.57%

Upside

Upgraded

12/08/25

Novartis AG (NOVN) was upgraded to a Buy Rating at J.P. Morgan

Thibault Boutherin

Morgan Stanley

CHF110→CHF115

Buy

9.09%

Upside

Upgraded

12/03/25

Morgan Stanley upgrades Novartis AG (NOVN) to a Buy

Sachin Jain

Bank of America Securities

CHF111→CHF117

Buy

10.98%

Upside

Upgraded

11/25/25

Novartis AG: Strong Growth Potential Amid Patent Expirations with Robust Pipeline and Strategic Phase III Trials

Emmanuel Papadakis

Deutsche Bank

CHF120

Buy

13.83%

Upside

Reiterated

11/21/25

Deutsche Bank Remains a Buy on Novartis AG (NOVN)

Shirley Chen

Barclays

CHF90

Sell

-14.63%

Downside

Reiterated

11/21/25

Barclays Remains a Sell on Novartis AG (NOVN)

David Evans

Kepler Capital

CHF106

Buy

0.55%

Upside

Reiterated

11/21/25

Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)

Matthew Weston

UBS

CHF102

Hold

-3.24%

Downside

Reiterated

11/20/25

Novartis AG (NOVN) Gets a Hold from UBS

Florent Cespedes

Bernstein

CHF108

Buy

2.45%

Upside

Reiterated

11/20/25

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Kerry Holford

Berenberg Bank

CHF89→CHF92

Hold

-12.73%

Downside

Reiterated

11/18/25

Berenberg Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

10/29/25

DZ BANK AG Keeps Their Buy Rating on Novartis AG (NOVN)

Benjamin Jackson CFA

Jefferies

CHF100→CHF110

Hold

4.34%

Upside

Reiterated

10/27/25

Jefferies Remains a Hold on Novartis AG (NOVN)

James Quigley

Goldman Sachs

CHF95→CHF94

Sell

-10.83%

Downside

Downgraded

09/12/25

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

Peter Verdult

Exane BNP Paribas

CHF95

Buy

-9.88%

Downside

Initiated

04/16/25

BNP Paribas Exane Starts Novartis (NOVN:SW) (NVS) at OutperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Novartis (NOVN:SW) (NYSE: NVS) with a Outperform rating and a price target of CHF95.00.

Eric Le Berrigaud

Stifel Nicolaus

CHF109

Hold

3.40%

Upside

Reiterated

01/31/25

Novartis AG: Balancing Strong Performance with Future Challenges - Hold Rating Maintained

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Vosser

J.P. Morgan

CHF95→CHF125

Buy

18.57%

Upside

Upgraded

12/08/25

Novartis AG (NOVN) was upgraded to a Buy Rating at J.P. Morgan

Thibault Boutherin

Morgan Stanley

CHF110→CHF115

Buy

9.09%

Upside

Upgraded

12/03/25

Morgan Stanley upgrades Novartis AG (NOVN) to a Buy

Sachin Jain

Bank of America Securities

CHF111→CHF117

Buy

10.98%

Upside

Upgraded

11/25/25

Novartis AG: Strong Growth Potential Amid Patent Expirations with Robust Pipeline and Strategic Phase III Trials

Emmanuel Papadakis

Deutsche Bank

CHF120

Buy

13.83%

Upside

Reiterated

11/21/25

Deutsche Bank Remains a Buy on Novartis AG (NOVN)

Shirley Chen

Barclays

CHF90

Sell

-14.63%

Downside

Reiterated

11/21/25

Barclays Remains a Sell on Novartis AG (NOVN)

David Evans

Kepler Capital

CHF106

Buy

0.55%

Upside

Reiterated

11/21/25

Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)

Matthew Weston

UBS

CHF102

Hold

-3.24%

Downside

Reiterated

11/20/25

Novartis AG (NOVN) Gets a Hold from UBS

Florent Cespedes

Bernstein

CHF108

Buy

2.45%

Upside

Reiterated

11/20/25

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Kerry Holford

Berenberg Bank

CHF89→CHF92

Hold

-12.73%

Downside

Reiterated

11/18/25

Berenberg Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

10/29/25

DZ BANK AG Keeps Their Buy Rating on Novartis AG (NOVN)

Benjamin Jackson CFA

Jefferies

CHF100→CHF110

Hold

4.34%

Upside

Reiterated

10/27/25

Jefferies Remains a Hold on Novartis AG (NOVN)

James Quigley

Goldman Sachs

CHF95→CHF94

Sell

-10.83%

Downside

Downgraded

09/12/25

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

Peter Verdult

Exane BNP Paribas

CHF95

Buy

-9.88%

Downside

Initiated

04/16/25

Eric Le Berrigaud

Stifel Nicolaus

CHF109

Hold

3.40%

Upside

Reiterated

01/31/25

Novartis AG: Balancing Strong Performance with Future Challenges - Hold Rating Maintained

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis AG

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+2.23%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +2.23% per trade.

3 Months

xxx

Success Rate

21/28 ratings generated profit

Average Return

+3.13%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +3.13% per trade.

1 Year

David EvansKepler Capital

Success Rate

28/28 ratings generated profit

Average Return

+11.78%

reiterated a buy rating 22 days ago

Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.78% per trade.

2 Years

xxx

Success Rate

28/28 ratings generated profit

Average Return

+18.32%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +18.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOVN has received 19 Buy Ratings, 13 Hold Ratings, and 3 Sell Ratings. NOVN average Analyst price target in the past 3 months is 107.18.

Each month's total comprises the sum of three months' worth of ratings.

NOVN Financial Forecast

NOVN Earnings Forecast

Next quarter’s earnings estimate for NOVN is CHF1.57 with a range of CHF1.53 to CHF1.68. The previous quarter’s EPS was CHF1.80. NOVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NOVN has Performed in-line its overall industry.

NOVN Sales Forecast

Next quarter’s sales forecast for NOVN is CHF11.02B with a range of CHF10.86B to CHF11.55B. The previous quarter’s sales results were CHF11.13B. NOVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NOVN has Performed in-line its overall industry.

NOVN Stock Forecast FAQ

What is CH:NOVN’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis AG’s 12-month average price target is 107.18.

What is CH:NOVN’s upside potential, based on the analysts’ average price target?

Novartis AG has 1.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis AG a Buy, Sell or Hold?

Novartis AG has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 2 sell ratings.

What is Novartis AG’s share price target?

The average share price target for Novartis AG is 107.18. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF125.00 ,and the lowest forecast is CHF90.00. The average share price target represents 1.67% Increase from the current price of CHF105.42.

What do analysts say about Novartis AG?

Novartis AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Novartis AG?

To buy shares of CH:NOVN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novartis AG (NOVN) Stock Forecast & Price Target

NOVN Analyst Ratings

NOVN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis AG

NOVN Analyst Recommendation Trends

NOVN Financial Forecast

NOVN Earnings Forecast

NOVN Sales Forecast

NOVN Stock Forecast FAQ

Detailed List of Analyst Forecasts